Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | PYGM | P11217 | 3/20 | 0.57 |
| ▸ | PYGL | P06737 | 2/20 | 0.57 |
| ▸ | CACNA1F | O60840 | 4/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29926641 | 1.00 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL7448031 | 1.00 | CYP1A2 (0.64) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL20801670 | 0.92 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL10901945 | 0.87 | CACNA1F (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL10900930 | 0.87 | CACNA1F (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL10901934 | 0.87 | CACNA1F (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL10900920 | 0.87 | CACNA1F (0.53) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL8370860 | 0.85 | MEN1 (0.58) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL11688678 | 0.85 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL11688660 | 0.85 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115177585-A | Nimodipine oral solution and preparation method thereof | 浙江普利药业有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20180098977-A1 | SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING POLYMORPHIC NIMODIPINE FORM 2 PREPARED BY A SOLVENT EVAPORATION PROCESS | EDGE THERAPEUTICS, INC | 2018-04-12 | — | — | US | disclosed |
| US-9914752-B2 | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20160243188-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2016-08-25 | — | — | US | disclosed |
| US-9399019-B2 | Polymorph compositions, methods of making, and uses thereof | EVONIK CORPORATION (US) | 2016-07-26 | — | — | US | disclosed |
| US-20140271895-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | EDGE THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-8821944-B1 | Polymorph compositions, methods of making, and uses thereof | EVONIK CORPORATION | 2014-09-02 | — | — | US | disclosed |
| US-20130310328-A1 | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders | BAUSCH HEALTH, CANADA INC. (CA) | 2013-11-21 | — | — | US | disclosed |
| US-20130302431-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | EVONIK CORPORATION | 2013-11-14 | — | — | US | disclosed |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-25 | — | — | US | disclosed |
| EP-0555302-A1 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-18 | — | — | EP | disclosed |
| WO-1992007564-A2 | METHOD OF TREATING DEMYELINATING DISEASE | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-14 | — | — | WO | disclosed |
| US-4504476-A | Method of administering calcium channel blocking agents | SCHWARTZ ARNOLD | 1985-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098977-A1 | SCALABLE MICROPARTICULATE FORMULATIONS CONTAINING POLYMORPHIC NIMODIPINE FORM 2 PREPARED BY A SOLVENT EVAPORATION PROCESS | CACNA1B, NIM1K, SLC6A4 | CYP1A2 470/4885CYP3A4 183/4885CYP2C9 550/4885 |
| US-20020049155-A1 | Cobalamin compounds useful as cardiovascular agents and as imaging agents | APOB, MMAB, CBS | CYP1A2 1311/4885CYP3A4 1154/4885CYP2C9 578/4885 |
| US-20140271895-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | PGF, BDNF, PYGB | CYP1A2 1222/4885CYP3A4 552/4885CYP2C9 1360/4885 |
| US-20130302431-A1 | Polymorph Compositions, Methods of Making, and Uses Thereof | PGF, BDNF, PYGB | CYP1A2 1222/4885CYP3A4 552/4885CYP2C9 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.